Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
| ▸ | CXCL8 | P10145 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29431315 | 1.00 | CYP1A2 (0.62) | CYP1A2KDM4EMAPTSMN1; SMN2LMNA | |
| SCHEMBL3110927 | 0.83 | SMN1; SMN2 (0.47) | CYP1A2KDM4EMAPTSMN1; SMN2LMNA | |
| SCHEMBL2178576 | 0.83 | SMN1; SMN2 (0.47) | CYP1A2KDM4EMAPTSMN1; SMN2LMNA | |
| SCHEMBL2561240 | 0.81 | FFAR1 (0.54) | CYP1A2KDM4EMAPTSMN1; SMN2LMNA | |
| SCHEMBL7633274 | 0.80 | LMNA (0.58) | CYP1A2SMN1; SMN2LMNAP2RX7CASP3 | |
| SCHEMBL28121426 | 0.80 | CASP3 (0.46) | CYP1A2KDM4EMAPTSMN1; SMN2LMNA | |
| SCHEMBL16540510 | 0.79 | P2RX7 (0.51) | CYP1A2KDM4EMAPTSMN1; SMN2LMNA | |
| SCHEMBL11348757 | 0.79 | SMN1; SMN2 (0.43) | CYP1A2KDM4EMAPTSMN1; SMN2LMNA | |
| SCHEMBL4126633 | 0.79 | P2RX7 (0.45) | CYP1A2KDM4EMAPTSMN1; SMN2LMNA | |
| SCHEMBL3064043 | 0.78 | KDM4E (0.65) | CYP1A2KDM4EMAPTAKR1B1CXCL8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106366034-B | A kind of preparation method of 3-Pyridineacetic Acid hydrochloride | 南京红太阳生物化学有限责任公司 | 2019-09-03 | — | — | CN | claimed |
| CN-106366034-A | Preparation method of 3-pyridylacetic acid hydrochloride | 南京红太阳生物化学有限责任公司 | 2017-02-01 | — | — | CN | claimed |
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2026-04-02 | — | — | US | disclosed |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12459942-B2 | Inhibiting (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4524133-A2 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119215031-A | Arylaniline and heteroaryl aniline compounds for the treatment of skin cancer | 恩福莱克逊治疗有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20240376095-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | SCHR¿DINGER, LLC | 2024-11-14 | — | — | US | disclosed |
| EP-3939658-B1 | SUBSTITUTED BENZOPYRROLE AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | BIOCRYST PHARM INC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240294494-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-09-05 | — | — | US | disclosed |
| CN-114984003-B | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20050054631-A1 | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-10 | — | — | US | disclosed |
| EP-0254545-B1 | DIAMINE COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-06 | — | — | EP | disclosed |
| US-5182289-A | Pyrrolo 2,3-b!Pyridin-2-one Derivatives | SCHERING CORPORATION (US) | 1993-01-26 | — | — | US | disclosed |
| WO-1991018902-A1 | SUBSTITUTED 1-H-PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDES | SCHERING CORPORATION (US) | 1991-12-12 | — | — | WO | disclosed |
| US-5023265-A | Antiinflammatory agent; inhibits both 5-lipoxygenase and cyclooxygenase; rheumatoid arthritis, bursitis, tendonitis, gout; side effect reduction | SCHERING CORPORATION (US) | 1991-06-11 | — | — | US | disclosed |
| EP-0419561-A1 | HETEROBICYCLIC COMPOUNDS HAVING ANTIINFLAMMATORY ACTIVITY | SCHERING CORPORATION (US) | 1991-04-03 | — | — | EP | disclosed |
| WO-1989012637-A1 | HETEROBICYCLIC COMPOUNDS HAVING ANTIINFLAMMATORY ACTIVITY | SCHERING CORPORATION (US) | 1989-12-28 | — | — | WO | disclosed |
| EP-0347698-A1 | Heterobicyclic compounds having antiinflammatory activity | SCHERING CORPORATION (US) | 1989-12-27 | — | — | EP | disclosed |
| EP-0254545-A2 | Diamine compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459942-B2 | Inhibiting (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | CYP1A2 4794/4885KDM4E 3386/4885MAPT 3244/4885 |
| US-20050054631-A1 | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) | PARP1, PARP11, PARP3 | CYP1A2 769/4885KDM4E 1305/4885MAPT 2114/4885 |
| US-20240294494-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | C9, C5, C1QBP | CYP1A2 170/4885KDM4E 2522/4885MAPT 1251/4885 |
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | TFPI, F3, BTK | CYP1A2 948/4885KDM4E 1536/4885MAPT 263/4885 |
| US-20240376095-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | CYP1A2 4753/4885KDM4E 3490/4885MAPT 3318/4885 |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | SUB1, AHR, NCOA3 | CYP1A2 110/4885KDM4E 2358/4885MAPT 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.